Table 1.
BCVA and CRT for ranibizumab and dexamethasone implant, respectively. P values present comparisons to baseline for each group.
| Ranibizumab | p Value | Dexamethasone implant | p Value | |
|---|---|---|---|---|
| BCVA (in letters) | ||||
| Baseline (mean ± SD) | 74.78 ± 14.85 (n = 9) | 67.22 ± 10.52 (n = 9) | ||
| Week 2 (mean ± SD) | 81.78 ± 9.56 (n = 9) | 0.021 | 71.00 ± 13.08 (n = 9) | 0.160 |
| Week 4 (mean ± SD) | 80.33 ± 7.84 (n = 9) | 0.160 | 69.38 ± 15.16 (n = 9) | 0.610 |
| Week 8 (mean ± SD) | 83.33 ± 6.33 (n = 9) | 0.058 | 77.13 ± 5.59 (n = 8) | 0.035 |
| Week 12 (mean ± SD) | 83.33 ± 7.52 (n = 9) | 0.038 | 74.38 ± 6.84 (n = 8) | 0.260 |
| Week 16 (mean ± SD) | 82.44 ± 8.88 (n = 9) | 0.018 | 77.00 ± 4.79 (n = 5) | 0.279 |
| Week 20 (mean ± SD) | 84.88 ± 8.88 (n = 9) | 0.008 | 74.60 ± 11.99 (n = 5) | 1.00 |
| CRT (μm) | ||||
| Baseline (mean ± SD) | 440.89 ± 144.47 (n = 9) | 471.33 ± 122.60 (n = 9) | ||
| Week 2 (mean ± SD) | 384.67 ± 106.08 (n = 9) | 0.011 | 363.78 ± 77.53 (n = 9) | 0.011 |
| Week 4 (mean ± SD) | 381.00 ± 114.64 (n = 9) | 0.008 | 373.75 ± 85.67 (n = 9) | 0.017 |
| Week 8 (mean ± SD) | 376.44 ± 119.24 (n = 9) | 0.011 | 353.75 ± 97.13 (n = 8) | 0.012 |
| Week 12 (mean ± SD) | 365.56 ± 106.21 (n = 9) | 0.011 | 422.13 ± 142.46 (n = 8) | 0.092 |
| Week 16 (mean ± SD) | 379.33 ± 119.59 (n = 9) | 0.051 | 350.20 ± 94.57 (n = 5) | 0.043 |
| Week 20 (mean ± SD) | 363.56 ± 108.54 (n = 9) | 0.028 | 370.80 ± 126.90 (n = 5) | 0.500 |
p values are displayed for each group. Bonferri correction was used for adjustment for multiple testing. Statistically significant p values after correction are displayed in bold.
BCVA = Best corrected visual acuity, CRT = central retinal thickness, SD = standard deviation.